175 related articles for article (PubMed ID: 17309184)
1. Bone scintigraphy in the monitoring of treatment effect of bisphosphonates in bone metastatic breast cancer.
Chavdarova L; Piperkova E; Tsonevska A; Timcheva K; Dimitrova M
J BUON; 2006; 11(4):499-504. PubMed ID: 17309184
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer.
Abe K; Sasaki M; Kuwabara Y; Koga H; Baba S; Hayashi K; Takahashi N; Honda H
Ann Nucl Med; 2005 Oct; 19(7):573-9. PubMed ID: 16363622
[TBL] [Abstract][Full Text] [Related]
3. 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer.
Van Den Bossche B; D'haeninck E; De Winter F; Van Belle S; Dierckx RA; Van De Wiele C
Nucl Med Commun; 2004 Aug; 25(8):787-92. PubMed ID: 15266172
[TBL] [Abstract][Full Text] [Related]
4. [Whole-body bone scintigraphy in the diagnosis and follow-up of the evolution of breast cancer].
Muşat E; Stefănescu C; Rusu V
Rev Med Chir Soc Med Nat Iasi; 1999; 103(1-2):163-9. PubMed ID: 10756905
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of whole-body MRI and bone scintigraphy in the detection of osseous metastases in patients with breast cancer--A Prospective Double-Blinded Study at two Hospital Centers].
Ohlmann-Knafo S; Kirschbaum M; Fenzl G; Pickuth D
Rofo; 2009 Mar; 181(3):255-63. PubMed ID: 19229791
[TBL] [Abstract][Full Text] [Related]
6. Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.
Morris PG; Poznak CV; Modi S; Mak AF; Patil S; Larson S; Hudis CA; Divgi C; Grewal RK
Clin Breast Cancer; 2010 Feb; 10(1):33-9. PubMed ID: 20133256
[TBL] [Abstract][Full Text] [Related]
7. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.
Cook GJ; Houston S; Rubens R; Maisey MN; Fogelman I
J Clin Oncol; 1998 Oct; 16(10):3375-9. PubMed ID: 9779715
[TBL] [Abstract][Full Text] [Related]
8. Spectral parametric segmentation of contrast-enhanced dual-energy CT to detect bone metastasis: feasibility sensitivity study using whole-body bone scintigraphy.
Lee YH; Kim S; Lim D; Suh JS; Song HT
Acta Radiol; 2015 Apr; 56(4):458-64. PubMed ID: 24714734
[TBL] [Abstract][Full Text] [Related]
9. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer.
Yang SN; Liang JA; Lin FJ; Kao CH; Lin CC; Lee CC
J Cancer Res Clin Oncol; 2002 Jun; 128(6):325-8. PubMed ID: 12073051
[TBL] [Abstract][Full Text] [Related]
10. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
11. Relation between pain and skeletal metastasis in patients with prostate or breast cancer.
Levren G; Sadik M; Gjertsson P; Lomsky M; Michanek A; Edenbrandt L
Clin Physiol Funct Imaging; 2011 May; 31(3):193-5. PubMed ID: 21114613
[TBL] [Abstract][Full Text] [Related]
12. Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma.
Alam MS; Takeuchi R; Kasagi K; Misaki T; Miyamoto S; Iida Y; Hidaka A; Konishi J
Thyroid; 1997 Oct; 7(5):705-12. PubMed ID: 9349573
[TBL] [Abstract][Full Text] [Related]
13. Bone scintigraphy in breast cancer: added value of hybrid SPECT-CT and its impact on patient management.
Sharma P; Singh H; Kumar R; Bal C; Thulkar S; Seenu V; Malhotra A
Nucl Med Commun; 2012 Feb; 33(2):139-47. PubMed ID: 22157698
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the attenuation of breast cancer bone metastasis in mice by zoledronic acid using (99m)Tc bone scintigraphy.
Wu C; Yang S; Sun Z; Han X; Ye Y; Liu S
Pathol Oncol Res; 2014 Jul; 20(3):747-54. PubMed ID: 24610002
[TBL] [Abstract][Full Text] [Related]
15. Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer.
Sohaib SA; Cook G; Allen SD; Hughes M; Eisen T; Gore M
Br J Radiol; 2009 Aug; 82(980):632-9. PubMed ID: 19221182
[TBL] [Abstract][Full Text] [Related]
16. 99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases.
Limouris GS; Voliotopoulos V; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1615-8. PubMed ID: 9179204
[TBL] [Abstract][Full Text] [Related]
17. Can 16-detector multislice CT exclude skeletal lesions during tumour staging? Implications for the cancer patient.
Groves AM; Beadsmoore CJ; Cheow HK; Balan KK; Courtney HM; Kaptoge S; Win T; Harish S; Bearcroft PW; Dixon AK
Eur Radiol; 2006 May; 16(5):1066-73. PubMed ID: 16402253
[TBL] [Abstract][Full Text] [Related]
18. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer.
Pecherstorfer M; Schilling T; Janisch S; Woloszczuk W; Baumgartner G; Ziegler R; Ogris E
J Nucl Med; 1993 Jul; 34(7):1039-44. PubMed ID: 8315476
[TBL] [Abstract][Full Text] [Related]
19. [New criteria for scintigraphic follow-up of bone metastases following radiotherapy. Results of functional scintigraphy using 99mTc-MDP].
Knop J; Stritzke P; Langendorff G
Nuklearmedizin; 1985 Dec; 24(5-6):238-43. PubMed ID: 4094901
[TBL] [Abstract][Full Text] [Related]
20. Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: a multicenter, multiple-reader, multiple-case study.
Sadik M; Suurkula M; Höglund P; Järund A; Edenbrandt L
J Nucl Med; 2009 Mar; 50(3):368-75. PubMed ID: 19223423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
